盐酸曲马多控释片治疗中重度非癌性肌肉骨骼慢性疼痛的持久缓解作用
Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain.
机构信息
Department of Medicine and Surgery Sciences, University of Bologna, Via Massarenti n. 9, 40138, Bologna, Italy,
出版信息
Pain Ther. 2015 Jun;4(1):107-17. doi: 10.1007/s40122-014-0030-6. Epub 2015 Jan 6.
INTRODUCTION
Despite opioids' recognized role in the treatment of moderate/severe musculoskeletal chronic pain, their long-term benefits need investigation. We explored the lasting analgesic efficacy, tolerability, influence on life quality, and chronicity stage of the novel prolonged release (PR) opioid, tapentadol, in 30 outpatients.
METHODS
We evaluated patients' pain intensity and relief (Numerical Rating Scale; NRS), adverse effects, sleep quality, treatment satisfaction, health status (12-questions Health-Survey; SF-12), chronicity stage (Italian Mainz Pain-Staging System; I-MPSS) at 10, 30, 60, and 90 days after tapentadol prescription.
RESULTS
At follow-ups, the investigated outcomes showed an overall statistically significant (Wilcoxon signed-rank test) improvement and remained stable over time, as did the health status and chronicity stage. Adverse effects were limited, transitory, and tolerable.
CONCLUSIONS
Twelve weeks of PR tapentadol in outpatients with moderate/severe chronic musculoskeletal pain showed satisfactory analgesic efficacy and tolerability, and had a positive influence on life quality and chronicity stage. The results are robust enough to warrant a subsequent study with a larger sample and a longer observation period.
简介
尽管阿片类药物已被认可用于治疗中重度肌肉骨骼慢性疼痛，但仍需研究其长期疗效。我们探究了新型缓释（PR）阿片类药物盐酸他喷他多在 30 名门诊患者中的长期镇痛疗效、耐受性、对生活质量的影响以及慢性阶段。
方法
我们在盐酸他喷他多处方后 10、30、60 和 90 天评估了患者的疼痛强度和缓解（数字评分量表；NRS）、不良反应、睡眠质量、治疗满意度、健康状况（12 项健康调查；SF-12）和慢性阶段（意大利美因茨疼痛分期系统；I-MPSS）。
结果
在随访中，调查结果显示总体上具有统计学显著意义（Wilcoxon 符号秩检验），且随时间推移保持稳定，健康状况和慢性阶段也是如此。不良反应有限、短暂且可耐受。
结论
12 周的 PR 盐酸他喷他多治疗中重度慢性肌肉骨骼疼痛的门诊患者显示出令人满意的镇痛疗效和耐受性，并对生活质量和慢性阶段产生积极影响。结果足够稳健，值得进行后续研究，扩大样本量并延长观察期。
Zotero 插件